EcoDrugPlus

Permeability Factor 2-Like

Ensembl ID : ENSOKIG00005018117
Gene Symbol: LOC109883089
2 Cross references
178 Possible Orthologues:

Permeability Factor 2-Like

Ensembl ID : ENSOKIG00005018132
Gene Symbol: LOC109883089
2 Cross references
178 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSOKIG00005047567
Gene Symbol: PPARD
3 Cross references
345 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSOKIG00005011613
Gene Symbol: PPARD
3 Cross references
345 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSOKIG00005000160
Gene Symbol: PPARG
3 Cross references
389 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha

Ensembl ID : ENSOKIG00005022177
Gene Symbol: LOC109867330
3 Cross references
390 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha-Like

Ensembl ID : ENSOKIG00005004015
Gene Symbol: LOC109897821
3 Cross references
390 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Delta

Ensembl ID : ENSOKIG00005011188
Gene Symbol: LOC109869520
3 Cross references
389 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Gamma-Like

Ensembl ID : ENSOKIG00005015625
Gene Symbol: LOC109869769
2 Cross references
333 Possible Orthologues:

Phosphatidylinositol 3,4,5-Trisphosphate 5-Phosphatase 1

Ensembl ID : ENSOKIG00005027688
Gene Symbol: LOC109881931
2 Cross references
208 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Gamma

Ensembl ID : ENSOKIG00005021261
Gene Symbol: LOC109872010
3 Cross references
192 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Gamma

Ensembl ID : ENSOKIG00005005364
Gene Symbol: LOC109898154
2 Cross references
155 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).